Search PubMed⌕ Search

Biomedical subjects

H Gallais

Publications and source records attributed to H Gallais.

At least 55 records · Page 3Linked to original sources
PubMed1986

Incidence, clinical observations and risk factors in the severe form of Mediterranean spotted fever among patients admitted to hospital in Marseilles 1983-1984.

Seven of 142 cases (5%) of Mediterranean spotted fever admitted to hospital in Marseilles in 1983 and 1984 were severe. All of them were confirmed by specific laboratory tests. The disease resembles Rocky Mountain spotted fever with purpuric exanthem, confusion, renal insufficiency, hypoxaemia, thrombocytopenia, hyponatraemia and hypocalcaemia. Two patients died. The predisposing factors for severity were old age, alcoholism, heavy smoking, respiratory insufficiency and glucose-6-phosphate dehydrogenase deficiency.

Adult↗
PubMed1986

Ciprofloxacin therapy for Mediterranean spotted fever.

We report the treatment of five patients with Mediterranean spotted fever with the antimicrobial agent ciprofloxacin. The treatment was administered intravenously for 2 days and then perorally for 8 days. All five patients were cured. These preliminary data seem to correlate with the in vitro activity of ciprofloxacin against Rickettsia conorii.

Adult↗
PubMed1986

Mediterranean spotted fever: clinical, laboratory and epidemiological features of 199 cases.

Most previous studies of Mediterranean spotted fever (MSF) have included cases that either were not laboratory-confirmed or were confirmed by the Weil-Felix test. The authors report the detailed clinical, laboratory and epidemiological features of 199 serologically-confirmed cases of MSF (by microimmunofluorescence). This work demonstrates that the disease is difficult to diagnose, especially at the beginning; that it can be fatal (2.5% of cases); and that a rapid and specific diagnosis is necessary to identify atypical cases. Epidemiological features such as season (summer essentially), presence of a dog, and travel in an endemic area (the Mediterranean Basin) are important in the diagnosis. In such cases fever associated with rash have to be considered and treated as MSF.

Adolescent↗
PubMed1985

[Epidemiologic aspects of Mediterranean boutonneuse fever in the south of Corsica].

During Summer 1984 was conducted a prospective study concerning Mediterranean Spotted Fever (a rickettsiosis due to Rickettsia conorii) in the south of Corsica. The prevalence of symptomatic and typical cases was 48 per 100,000. A seroepidemiologic study made on blood donors of the same area shows a prevalence of antibody to R. conorii at 12% for a dilution of 1/32, 4.8% for 1/64 and 2.5% for 1/128. This study show that Corsica is, as well as south of France, Sicily and Spain an endemic country for Mediterranean Spotted Fever and that asymptomatic cases are mostly frequent.

Adolescent↗
PubMed1984

Laboratory diagnosis of Mediterranean spotted fever by immunofluorescent demonstration of Rickettsia conorii in cutaneous lesions.

Indirect immunofluorescent staining was performed on cryostat sections of skin biopsy specimens from 21 patients. In six of the 11 cases finally diagnosed as Mediterranean spotted fever, coccobacillary forms of Rickettsia conorii were identified in these sections. A factor recognized as contributing to false-negative results was prior treatment with tetracycline. No false-positive results were obtained for 10 patients whose final diagnosis was not Mediterranean spotted fever. This laboratory test can aid in the early diagnosis of severe and atypical forms of Mediterranean spotted fever.

Adolescent↗
PubMed1984

[Serological diagnosis of Mediterranean boutonneuse fever].

Mediterranean spotted fever is a rickettsiosis due to R. conori. The authors have tested 2 serological reactions available in this disease: Weil-Felix (WF) and indirect immunofluorescent antibody test IF. IF, tested on 184 sera is sensitive (100% of positivity 30 days after the onset of the disease) and specific if a four fold in two sera is obtained at a level upper than: 80. The WF tested on 112 sera is not specific and its sensitivity is poor.

Agglutination Tests↗
PubMed1984

[Treatment of typhoid fever with cefoperazone].

Cefoperazone was given parenterally to 10 patients (9 woman and 1 man, aged 19 to 75 years) with positive blood cultures for Salmonella typhi (9 cases) or Salmonella paratyphi A (1 case). Daily dosage was 0.5 g on the first day, 1 g on the second and 2 g on the third. Five patients had 4 g on the fourth day. Average time to defervescence was five days. There were no relapses. Cefoperazone is therefore satisfactory for treating typhoid fever, especially caused by ampicillin- or chloramphenicol-resistant bacteria.

Adult↗
PubMed1983

[Campylobacter fetus fetus bacteremia. Review of the literature apropos of 2 cases].

The authors report two cases of bacteremia due to Campylobacter fetus fetus (also called C. fetus intestinalis). One was a 22-year-old female, under treatment for active systemic lupus erythematosus, who died. The other was a fifty-year-old male, in a poor general condition, who had a self-limited acute febrile dysentery. In this patient, C. fetus fetus was found in stools after apparent recovery, raising the problem of healthy carriers. A review of the literature shows 64 other such cases.

Adult↗
PubMed1983

[Malignant form of Mediterranean boutonneuse fever. 6 cases].

Six cases of severe Mediterranean boutonneuse fever are reported. The clinical diagnosis, based on the presence of summer fever with an erythematous rash plus an escharr in three patients, was confirmed by serology (microagglutination in 1 case, indirect immunofluorescence in 4). The symptoms resembled those of Rocky Mountain spotted fever associating, as they did, a purpuric rash with neurological signs (impaired consciousness in all 6 cases, convulsion in 2), respiratory symptoms (5) and digestive signs (diarrhoea in 1 case, enlargement of the liver in 4). Laboratory examinations showed thrombopenia (6), rise in serum transaminases (5), LDH (5) and CPK (6), increased in blood urea and creatinine levels (6), hyponatraemia (6), hypokaliaemia (5) and hypocalcaemia (5). Two patients treated with doxycycline recovered and 4 died. Among these, 1 had received erythromycin, 1 a tetracycline and 1 doxycycline.

Adolescent↗
PubMed1983

Midazolam and oxazepam in the treatment of insomnia in hospitalized patients.

Fifty-nine hospitalized patients participated in a double-blind study: 19 received 15 mg midazolam, 20 received 50 mg oxazepam, and 20 placebo. The three groups were comparable with regard to age, sex, height, weight, and degree and type of insomnia. The sleep-onset latency was shorter with midazolam than with placebo or oxazepam (Mann-Whitney test, alpha less than 0.05). With regard to total sleep duration and the number of nocturnal awakenings, there was no difference between the midazolam and oxazepam groups, whereas there was a difference between these two groups and placebo. More subjects of the midazolam group felt calm and refreshed on awakening. Safety, assessed by clinical examination and laboratory tests, was excellent. This study confirms the usefulness of midazolam in treating 'early' insomnia, i.e. difficulty in falling asleep.

Anti-Anxiety Agents↗
PubMed1983

[Mediterranean boutonneuse fever. Apropos of 154 recent cases].

The Mediterranean spotted fever is always present in the south of France. The actual incidence is unknown. The disease appears in summer. The diagnostic is based on the association of fever, "black spot" and exanthema and/or a seroconversion. Indirect immunofluorescence is the most used technique. Some patients have severe complications: neurologic, cardiovascular, renal, thrombopenia. These cases look like Rocky Mountain Spotted Fever. The treatment is based on tetracycline.

Adolescent↗